06Jul 2023
Screening for pre‐eclampsia by maternal serum glycosylated fibronectin at 11−13 weeks’ gestation

Screening for pre‐eclampsia by maternal serum glycosylated fibronectin at 11−13 weeks’ gestation

Screening for preterm and term preeclampsia (PE) was assessed in a case-control study using various maternal factors and biomarkers. Maternal serum glycosylated fibronectin (GlyFn), mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), and serum placental growth factor (PlGF) were measured in stored samples. The study included women with PE, gestational hypertension (GH), and normotensive controls. Patient-specific risks of PE and GH were derived using a competing risks model. The triple test combining maternal risk factors with MAP, UtA-PI, and PlGF showed the highest detection rate (80%) for PE at <37 weeks gestation. Screening for PE at ≥37 weeks' gestation had a poorer performance. The triple test also improved detection rates for GH.

  • #gynaecology - ivf

Like

Save

Share